Avelumab阿维鲁单抗阿维鲁单抗,1537032-82-

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Avelumab

CAS No. : 1537032-82-8

MCE 国际站：Avelumab

产品活性：Avelumab 是一个人 IgG1 抗 PD-L1 单克隆抗体，具有潜在的抗体依赖性细胞介导的细胞毒性作用。

研究领域：Immunology/Inflammation

作用靶点：PD-1/PD-L1

In Vitro: Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity property. Avelumab increases NK-cell lysis 3.1-fold (P=0.01) in JHC7 cells relative to isotype control. When the cells are treated with IFN-γ, Avelumab markedly enhances NK-cell lysis relative to isotype control in the following cell lines: JHC7 (7.56-fold; P=0.001), UM-Chor1 (7.34-fold; P<0.001), U-CH2 (2.6 fold; P=0.008), MUG-Chor1 (8.38-fold; P=0.0016). Avelumab effectively increases antibody-dependent cell-mediated cytotoxicity (ADCC) of both the non-cancer stem cell (CSC) and CSC subpopulations to the same degree. Results also demonstrate that the addition of Avelumab increases the frequency of antigen-specific multifunctional CD8⁺ T cells by more than fivefold, relative to the isotype control in CEFT-stimulated peripheral blood mononuclear cells (PBMCs).

In Vivo: Measurement of individual tumors clearly shows a slowing of tumor growth in the Avelumab-treated mice. By day 36 post-tumor implantation, there is a significant (P<0.01) reduction in the average tumor volume of the Avelumab-treated mice. Reduction in MB49 tumor growth in the mice treated with Avelumab is durable and leads to a significant (P<0.05) improvement in percent survival. Avelumab treatment of 10 mice with bladder tumors results in complete tumor regression in 8 mice, confirmed by histopathology. However, in mice depleted of either CD4 or CD8 cells, Avelumab treatment is much less effective in controlling bladder tumor burden with tumor breakthrough occurring in a higher frequency in mice depleted of CD4 T cells.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  Bioactive Compound Library Plus  |  Atezolizumab  |  Pembrolizumab  |  Cilengitide  |  BMS-1  |  Nivolumab  |  BMS-202  |  JQ-1 (carboxylic acid)  |  Durvalumab  |  Tomivosertib  |  Anti-Mouse PD-L1 Antibody (10F.9G2)  |  Anti-Mouse PD-1 Antibody (RMP1-14)  |  Pembrolizumab (anti-PD-1)  |  Sulindac  |  CA-170  |  BMS-1166  |  INCB086550  |  Camrelizumab  |  Fraxinellone  |  Tislelizumab  |  PD-1/PD-L1-IN-9  |  BMS-8  |  Sintilimab  |  PD-L1-IN-1  |  Evixapodlin  |  PROTAC PD-1/PD-L1 degrader-1  |  Toripalimab  |  Onvatilimab  |  PD-1-IN-17

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds